AGORACOM-JC « AGORACOM Small-cap Investor Relations Blog

Author Archive

Innocan $INNO.ca Pharma Announces Closing of Private Placement $CGC.ca $APHA $OVAT.ca $KHRN.ca

Posted by AGORACOM-JC at 8:41 AM on Thursday, December 31st, 2020

Announced that it has today closed a non-brokered private placement offering of 10,294,800 units of Innocan at a price of $0.23 per Units for aggregate gross proceeds of $2,367,804
All Common Shares and Warrants issued pursuant to the Offering will be subject to a four month statutory hold period commencing from the closing date under applicable securities laws.

Herzliya, Israel and Calgary, Alberta–(December 31, 2020) – Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF) (the “Company” or “Innocan”) is pleased to announce that it has today closed a non-brokered private placement offering of 10,294,800 units of Innocan (the “Units”) at a price of $0.23 per Units for aggregate gross proceeds of $2,367,804 (the “Offering”).

All Common Shares and Warrants issued pursuant to the Offering will be subject to a four month statutory hold period commencing from the closing date under applicable securities laws.

Each Unit consists of one common share in the capital of the Company (“Common Share”) and one-half of one common share purchase warrant (“Warrant”). Each whole Warrant entitles the holder to purchase one Common Share at a price of $0.35 for a period of three years from the date of issuance.

Following the date of issuance of the Warrants, if the daily volume weighted average trading price of the Common Shares on the Canadian Securities Exchange for any period of 30 consecutive trading days equals or exceeds $0.70, the Company may, upon providing written notice to the holders of the Warrants (the “Acceleration Notice”), accelerate the expiry date of the Warrants to the date that is 30 days following the date of the Acceleration Notice.

Innocan intends to use the proceeds of the Offering for general working capital and corporate purposes.

“Our investors continue to show confidence in the Company. We are delighted to complete this private placement” stated Iris Bincovich, Chief Executive Officer of Innocan. “Despite the holiday season and the four months hold period that applies to the Units”.

About Innocan

The Company, through its wholly owned Israeli subsidiary, Innocan Pharma Ltd. (“Innocan Israel”), is a pharmaceutical tech company that focuses on the development of several drug delivery platforms combining cannabidiol (“CBD“). Innocan Israel and Ramot at Tel Aviv University are collaborating on a new, revolutionary exosome-based technology that targets both central nervous system (CNS) indications and the Covid-19 Coronavirus using CBD. CBD-loaded exosomes hold the potential to help in the recovery of infected lung cells. This product, which is expected to be administrated by inhalation, will be tested against a variety of lung infections.

Innocan Israel signed a worldwide exclusive license agreement with Yissum, the commercial arm of the Hebrew University of Jerusalem to develop a CBD drug delivery platform based on a unique-controlled release liposome to be administrated by injection. Innocan Israel plans, together with Professor Berenholtz, Head of the Laboratory of Membrane and Liposome Research of the Hebrew University, to test the liposome platform on several potential indications. Innocan Israel is also working on a dermal product that integrates CBD with other pharmaceutical ingredients as well as the development and sale of CBD-integrated pharmaceuticals, including, but not limited to, topical treatments for relief of psoriasis symptoms as well as the treatment of muscle pain and rheumatic pain. The founders and officers of Innocan have commercially successful track records in the pharmaceutical and technology sectors in Israel and globally.

For further information, please contact:

For Innocan Pharma Corporation:
Iris Bincovich, CEO
+972-54-3012842
[email protected]

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Caution regarding forward-looking information

Certain information set forth in this news release, including, without limitation, information regarding the markets, requisite regulatory approvals and the anticipated timing for market entry, is forward-looking information within the meaning of applicable securities laws. By its nature, forward-looking information is subject to numerous risks and uncertainties, some of which are beyond Innocan’s control. The forward-looking information contained in this news release is based on certain key expectations and assumptions made by Innocan, including expectations and assumptions concerning the anticipated benefits of the products, satisfaction of regulatory requirements in various jurisdictions and satisfactory completion of requisite production and distribution arrangements.

Forward-looking information is subject to various risks and uncertainties which could cause actual results and experience to differ materially from the anticipated results or expectations expressed in this news release. The key risks and uncertainties include but are not limited to: general global and local (national) economic, market and business conditions; governmental and regulatory requirements and actions by governmental authorities; and relationships with suppliers, manufacturers, customers, business partners and competitors. There are also risks that are inherent in the nature of product distribution, including import / export matters and the failure to obtain any required regulatory and other approvals (or to do so in a timely manner) and availability in each market of product inputs and finished products. The anticipated timeline for entry to markets may change for a number of reasons, including the inability to secure necessary regulatory requirements, or the need for additional time to conclude and/or satisfy the manufacturing and distribution arrangements. As a result of the foregoing, readers should not place undue reliance on the forward-looking information contained in this news release concerning the timing of launch of product distribution. A comprehensive discussion of other risks that impact Innocan can also be found in Innocan’s public reports and filings which are available under Innocan’s profile at www.sedar.com.

Readers are cautioned that undue reliance should not be placed on forward-looking information as actual results may vary materially from the forward-looking information. Innocan does not undertake to update, correct or revise any forward looking information as a result of any new information, future events or otherwise, except as may be required by applicable law.

Tags: CBD Derma Cosmetics, CBD stocks, CSE, Facial Serum, Innocan, Khiron Life Sciences Corp, Ovation Science Inc., Relief & Go Pain Relief Spray
Posted in Innocan Pharma Corporation | Comments Off on Innocan $INNO.ca Pharma Announces Closing of Private Placement $CGC.ca $APHA $OVAT.ca $KHRN.ca

betterU $BTRU.ca Makes Significant Advances During 2020 $ARCL $CPLA $BPI $FC.ca

Posted by AGORACOM-JC at 8:07 AM on Thursday, December 31st, 2020

OTTAWA, ON / December 31, 2020 / betterU Education Corp. (TSXV:BTRU)(FSE:5OGA) (the “Company” or “betterU”) is pleased to provide an update on the development of the Company and the advances made over this last year. The following is a summary of the updates and agreements closed with individual press releases to follow in the new year.

Announced early 2020, betterU launched their beta version of their Enterprise SaaS Skills Development Platform called ‘Ready-To-Go’. While the Company was also impacted by the pandemic and many deals slowed in their development, betterU continued to push forward with Ready-To-Go and the beta clients with great success. The Company has advanced the platform from approximately 300 hosted courses in early 2020 to now over 3,700 courses across 200 categories. Combined with 800+ job role and 1,000+ subject based assessments, operating through a robust Learning Management System, betterU’s Ready-To-Go platform has gained a lot of interest around the world as the easiest all-in-one corporate solution for skills development and helping support job readiness.

While betterU’s beta program took a little longer to advance due to the slowdown in the market, the feedback from their clients provided valuable insight into finalizing a scalable, flexible, customizable, adaptable, multilingual solution that supports not only companies and governments, but also students, employees, underemployed and unemployed.

“I am so proud of the dedication and hard work of our team, board, advisors and partners that have worked closely with myself and betterU over this year to accomplish all that we have considering the circumstances. While there is still much work to do ahead of us, we now have proven solutions to achieve great results in 2021.” said Brad Loiselle, CEO betterU

In addition to the business update, the filing of the audited financial statements, MD&A and other related materials have been completed by the Company and DNTW and are in process to being made available on SEDAR. The delay in completion of the Audit was primary due to lack of responses from third-party confirmations with no material changes over last years audit. betterU is also currently working with their corporate legal team, Denton LLP and the Company’s Board of Directors to finalize the set-up of the Annual General Meeting (AGM) as well as working to ensure all disclosures are properly filed with TSXV and regulatory bodies to support trade resumption. The timelines and process are unknown at this time and the Company will provide updates after receiving notification from TSXV.

The following are the advancements that company has been making over 2020:

Unicaf and betterU execute strategic partnership and reseller agreement with plans to support thousands of students across Africa. Unicaf offers one of the most generous scholarship programmes available today having awarded so far over $100 million to more than 30,000 eligible applicants in 156 countries around the world. Full details of the partnership will be announced in January 2021.
NRCM and betterU execute strategic partnership and reseller agreement to support both business and the mass market of Morocco. NCRM, a subsidiary of MEDTECH Group, and 25 years focused on the technology industries include Banking, Retail and Governmental Operators. betterU and NRCM have already completely joint proposals for several government contracts and currently working on more. Full details of the partnership will be announced in January 2021.
Fuel Online and betterU execute strategic partnership and reseller agreement to support corporate skills development programs across 18 African countries. Fuel Online currently provides vocational training to over 200,000 people per week and the addition of betterU’s skills programs and platform will provide the next level of skills development programs. betterU will also be adding Fuel Online’s programs to their offering. Full details of the partnership will be announced in January 2021.
Paramount Staffing (USA) notified betterU on October 29th that they were selected as the only partner for skills development, with plans to develop a long-term partnership. In early 2020, Paramount Staffing, a $200+ Million people company and subsidiary of Proman, a $3 Billion staffing company headquartered in France, became one of betterU’s first beta customers for Ready-To-Go. Over the year, even during the constraints of the pandemic, betterU delivered top quality content, support and services. Paramount had been working with multiple learning providers that were inherited through their acquisitions over the years and decided after an extensive review that betterU was their partner of choice. Hear from their VP of Sales in this Video Testimonial. Full details of the opportunity will be announced in January 2021 as betterU and Paramount work to develop their combined 3-5 year plans.
betterU launched Skills Council of Canada (SSC) https://skillscouncil.ca/ to support a developing initiative to help upwards of 5,000 students across Canada to gain work experience and essential skills to be job ready. betterU’s brand SSC, will provide Work Integrated Learning (WIL) and skills development programs through betterU’s WIL+Skills platform with a core focus on Indigenous people and more vulnerable communities across Canada. betterU started their marketing and outreach campaigns October 2020 after receiving written approval from our collaborative partners. Outreach included connecting with Canadian educators, corporates, government, and Indigenous leaders, now with multiple partnership underway. Full details of this opportunity and associated partners will be announced in January 2021.

betterU’s beta skills program successful with Canada’s Positive Venture Group (PVG). betterU had curated multiple programs to be added to PVG’s branded platform which included over 200 learning paths focused on financial related jobs. PVG launched the first batch of courses for all employees which resulted with high reviews and success. Full details of the partnership growth will be announced in January 2021.
betterU launches their beta Reseller / Franchisee (Partners) program to support e-learning leaders looking to add Ready-To-Go to their own services or launch their own branded skills development platform, “powered by betterU”. The Partners model would enable those who already have a network of corporate partners or clients with the opportunity to support them in providing access to betterU’s thousands of courses, assessments, and a fully managed betterU service. betterU’s all-in-one skills platform has been developed to support scalability with a function that operates similar to a franchise. In order to grow betterU’s global reach, and network of sales partners, while ensuring betterU maintains control over the network, the Partners model is being tested. betterU is currently negotiating with possible Partners and full details of the partnership structure will be announced earlier 2021.
betterU established 100% owned operating entity, betterU Europe Ltd (“BEL”) in Dublin Ireland to help support developing opportunities for betterU across Africa and Europe.
betterU’s Corporate website is currently being updated with company advancements, programs, products and services. https://corporate.betteru.ca

betterU has many more growing opportunities in the pipeline including three completed RFPS for opportunities in the USA, Africa and Morocco. betterU has already been short listed for two of the RFPs and if successful will be announced. In addition, the Company has also received requests for additional strategic partnerships and resellers opportunities for organizations in Thailand, UAE and the USA.

The company has plans to increase their IR team to support more frequent public disclosures and business updates. Over this last year, betterU remained solely focused on the business to ensure the product pivot announced late 2019 was accomplishing the growth and validating the opportunity we expected would come.

“We were very pleased with the results achieved over this last year, despite the global challenges faced by many. Many companies local and abroad have been forced to close their doors, make pivots themselves to also overcome the challenges of this pandemic. betterU doubled down on our efforts to push forward for our shareholders and our vision. We thank all the people that have stayed supportive and we appreciate your patience. We are expecting great results and growth in 2021. Stay tuned!” said Brad Loiselle, CEO of betterU.

About betterU Education Corp.
betterU is an education-to-employment technology company offering an end-to-end solution leveraging business intelligence to automate skilling, reskilling, and upskilling for companies operating on domestic and global scales. The company supports all industries by providing them with everything an organization needs to launch and manage proper skills development programs, student work integrated learning and employee development, so that they can focus on what really matters: the growth of their people!

betterU’s Ready-To-Go platform provides access to a white labelled all-in-one skills platform that includes access to a library of 3,700 curated and developed skills courses, 800+ job role assessments, 1,000+ subject base assessments and a robust learning management system all hosted and supported by betterU. betterU also provides additional services to include a fully white labelled marketed program, in partnerships with betterU that includes a website that promotes the Company’s strategic partners Ready-To-Go program across their territory.

For more information, please visit https://corporate.betteru.ca

On behalf of the Board of Directors:
Brad Loiselle, CEO
1-(650) 267-8398
Email: [email protected]

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility

SOURCE: betterU Education Corp.

Tags: Byju, COVID-19, CSE, edtech, india, small cap stocks, stocks, tsx, tsx-v
Posted in betterU Education Corp | Comments Off on betterU $BTRU.ca Makes Significant Advances During 2020 $ARCL $CPLA $BPI $FC.ca

Kontrol $KNR $KNR.ca $KNR.c $KNRLF Retains Emerging Markets Consulting LLC for Investor Relations Advisory Services $SNE $MSFT $HON $GOOGL $QCOM

Posted by AGORACOM-JC at 7:21 AM on Thursday, December 31st, 2020

Emerging Markets Consulting, LLC (EMC) has been retained to provide investor and public relations services.
EMC specializes in helping small and mid-sized public companies establish brand awareness and increase market share to its customer base while improving visibility to the institutional and retail investment community.

TORONTO, Dec. 31, 2020 — Kontrol Energy Corp. ( CSE:KNR ) OTCQB:KNRLF ) FSE:1K8 ) (” Kontrol ” or ” Company “), a leader in smart buildings and cities through IoT, Cloud and SaaS technology, is pleased to announce that Emerging Markets Consulting, LLC (EMC) has been retained to provide investor and public relations services. EMC specializes in helping small and mid-sized public companies establish brand awareness and increase market share to its customer base while improving visibility to the institutional and retail investment community.

“With our anticipated stock exchange uplisting in 2021 and the recent launch of BioCloud, we believe this is an opportune time to share our story with a global investor audience,” says Paul Ghezzi, CEO of Kontrol.

James Painter, President of EMC, said, “We are pleased to represent Kontrol during the coming year. We have conducted our due diligence on the Company and have been very impressed with the management, share structure and overall business strategy.”

About Emerging Markets Consulting LLC

Based in Orlando, Florida, Emerging Markets Consulting, LLC (EMC) brings over 40 years combined experience in the investor relations industry. EMC is an international investor relations firm with affiliates around the world. EMC is relationship-driven and results-oriented with the goal of seeking attractive emerging companies and concentrating its resources and efforts to serve a limited number of high-quality clients. For more information, visit EMC’s website at www.emergingmarketsllc.com

About Kontrol BioCloud TM

BioCloud is a real-time analyzer designed to detect airborne viruses. It has been designed to operate as a safe space technology by sampling the air quality over time. With a proprietary detection chamber that can be replaced as needed, viruses are detected, and an alert system is created in the Cloud or over local intranet. BioCloud has been designed for spaces where individuals gather including classrooms, offices, retirement homes, hospitals, mass transportation and others. Additional information about Kontrol BioCloud can be found on its website at www.kontrolbiocloud.com

BioCloud is an air quality technology and not a medical device. The Company is not making any express or implied claims that its product has the ability to eliminate, cure or contain the COVID-19 (or SARS-2 Coronavirus). Safe Space Technology is a Kontrol Trademark.

About Kontrol Energy

Kontrol Energy Corp., a Canadian public company, is a leader in smart buildings and cities through IoT, Cloud and SaaS technology. Kontrol Energy provides a combination of software, hardware, and service solutions to its customers to improve energy management, air quality and continuous emission monitoring.

Additional information about Kontrol Energy Corp. can be found on its website at www.kontrolenergy.com and by reviewing its profile on SEDAR at www.sedar.com

https://www.facebook.com/kontrolenergy

https://twitter.com/kontrolenergy

https://www.linkedin.com/company/kontrol-energy-corp

For further information, contact:

Paul Ghezzi, Chief Executive Officer
[email protected] or [email protected]
Kontrol Energy Corp.
180 Jardin Drive, Unit 9, Vaughan, ON L4K 1X8
Tel: 905.766.0400, Toll free: 1.844.566.8123

Emerging Markets Consulting, LLC
James S. Painter, CEO
390 North Orange Ave Suite 2300
Orlando, Florida 32801
E-mail: [email protected] Web: www.emergingmarketsllc.com

Neither IIROC nor any stock exchange or other securities regulatory authority accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements

This news release contains “forward-looking information” within the meaning of applicable securities laws. All statements contained herein that are not clearly historical in nature may constitute forward-looking information. In some cases, forward-looking information can be identified by words or phrases such as “may”, “will”, “expect”, “likely”, “should”, “would”, “plan”, “anticipate”, “intend”, “potential”, “proposed”, “estimate”, “believe” or the negative of these terms, or other similar words, expressions and grammatical variations thereof, or statements that certain events or conditions “may” or “will” happen, or by discussions of strategy.

Where the Company expresses or implies an expectation or belief as to future events or results, such expectation or belief is based on assumptions made in good faith and believed to have a reasonable basis. Such assumptions include, without limitation, that sufficient capital will be available to the Company and that technology will be as effective as anticipated.

However, forward-looking statements are subject to risks, uncertainties, and other factors, which could cause actual results to differ materially from future results expressed, projected, or implied by such forward-looking statements. Such risks include, but are not limited to, that sufficient capital and financing cannot be obtained on reasonable terms, or at all, that technologies will not prove as effective as expected, that customers and potential customers will not be as accepting of the Company’s product and service offering as expected, and government and regulatory factors impacting the energy conservation industry. In particular, successful development and commercialization of the Kontrol BioCloud Analyzer are subject to the risk that the Kontrol BioCloud Analyzer may not prove to be successful in detecting the virus that causes COVID-19 effectively or at all, uncertainty of timing or availability of any regulatory approvals and Kontrol’s lack of track record in developing products for medical applications.

Accordingly, undue reliance should not be placed on forward-looking statements and the forward-looking statements contained in this press release are expressly qualified in their entirety by this cautionary statement. The forward-looking statements contained herein are made as at the date hereof and are based on the beliefs, estimates, expectations, and opinions of management on such date. Kontrol does not undertake any obligation to update publicly or revise any such forward-looking statements or any forward-looking statements contained in any other documents whether as a result of new information, future events or otherwise or to explain any material difference between subsequent actual events and such forward-looking information, except as required under applicable securities law. Readers are cautioned to consider these and other factors, uncertainties, and potential events carefully and not to put undue reliance on forward-looking information.

Tags: BioCloud, COVID-19, CSA, CSA Standards, CSE, energy conservation, google nest, stocks, tsx
Posted in Kontrol Energy Corp. | Comments Off on Kontrol $KNR $KNR.ca $KNR.c $KNRLF Retains Emerging Markets Consulting LLC for Investor Relations Advisory Services $SNE $MSFT $HON $GOOGL $QCOM

Kontrol $KNR $KNR.ca $KNR.c $KNRLF Receives $750,000 Emission Order Including BioCloud Sales and Initial BioCloud Order from Ontario Electricity Generator $SNE $MSFT $HON $GOOGL $QCOM

Posted by AGORACOM-JC at 11:48 AM on Wednesday, December 23rd, 2020

Announced a $750,000 order for its continuous emissions business which includes BioCloudTM units and a separate initial order from one of Ontario’s largest Electricity Generators
The continuous emissions and BioCloud revenues are anticipated to be recorded in Q1 2021

TORONTO, ON / December 23, 2020 / Kontrol Energy Corp. (CSE:KNR)(OTCQB:KNRLF)(FSE:1K8) (“Kontrol” or “Company“), a leader in smart buildings and cities through IoT, Cloud and SaaS technology, is pleased to announce a $750,000 order for its continuous emissions business which includes BioCloudTM units and a separate initial order from one of Ontario’s largest Electricity Generators. The continuous emissions and BioCloud revenues are anticipated to be recorded in Q1 2021.

“We are very pleased to receive a significant order in our core business with a US manufacturing customer which also includes 2 BioCloud units as part of a package sale,” says Paul Ghezzi, CEO of Kontrol. “Our corporate strategy is to quote BioCloud units as part of all new sales opportunities from our core business. In addition, we are pleased that one of Ontario’s largest Electricity Generators has ordered an initial 2 units of BioCloud. Both customers have additional scale potential with numerous facilities. Our recent product launch and technology walk-through in December was a success and has initiated accelerating interest in how BioCloud can help create safer spaces.”

Distribution Orders

To date the Company has received 40 initial distribution orders for delivery in January from its existing distribution network. The Company has entered into 6 distribution agreements (1 exclusive and 5 non-exclusive) and is in negotiations for various potential additional non-exclusive distributions agreements. Distribution is a key part of our go to market strategy that can allow the Company to scale quickly.

“In a short period of time since the official launch of BioCloud in December we have received strong interest and numerous distribution requests,” says Gary Saunders, VP Kontrol. “We envision many more agreements across the globe as we focus on growing the BioCloud business.”

As the Company continues to build its distribution business, we anticipate that distributors will be required to maintain a minimum of 250-unit sales per annum to retain non-exclusivity and distributor pricing. The Company’s internal goal is to have 30 regional distributors established by the end of Q1 2021.

Customer Pilots

The Company plans to begin numerous pilots with both existing customers of Kontrol and new potential customers. The purpose of the pilots is to provide potential customers with various specific application use cases across their facilities. The types of pilot customers will include the sectors of commercial real-estate, grocery stores, franchised restaurants, educational facilities and other. Subject to pilot customer approval Kontrol may announce customer pilots or may operate them under non-disclosure agreement.

Recurring Revenue

The BioCloud unit operates with a proprietary detection chamber. The retail price for the detection chamber consumable will range from $400 to $500 and the recommended replacement is three times per year or whenever the detection chamber comes into contact with SARS-CoV-2. Customers that purchase multiple units will receive volume discounts for the detection chamber.

Re-Agent Supply Chain

The detection chamber includes a specific re-agent system. To date the Company has been sourcing its re-agents from the United States. The Company has initiated discussions and testing to source its re-agents from Canadian based sources. By doing so it is seeking to add more of its supply chain in Canada but also reduce the costs of the detection chamber. Further updates will be provided following additional testing.

Essential Service

Kontrol and its manufacturing supply chain operate as an Essential Service provider and do not anticipate being impacted by applicable COVID-19 shutdowns.

About Kontrol BioCloudTM

Additional information about Kontrol BioCloud can be found on its website at www.kontrolbiocloud.com

About Kontrol Energy

Additional information about Kontrol Energy Corp. can be found on its website at www.kontrolenergy.com and by reviewing its profile on SEDAR at www.sedar.com

For further information, contact:

Paul Ghezzi, Chief Executive Officer
[email protected] or [email protected]
Kontrol Energy Corp.
180 Jardin Drive, Unit 9, Vaughan, ON L4K 1X8
Tel: 905.766.0400, Toll free: 1.844.566.8123

Neither IIROC nor any stock exchange or other securities regulatory authority accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements

SOURCE: Kontrol Energy Corp.

Tags: BioCloud, COVID-19, CSA, CSA Standards, CSE, energy conservation, google nest, stocks, tsx, tsx-v
Posted in Featured, Kontrol Energy Corp. | Comments Off on Kontrol $KNR $KNR.ca $KNR.c $KNRLF Receives $750,000 Emission Order Including BioCloud Sales and Initial BioCloud Order from Ontario Electricity Generator $SNE $MSFT $HON $GOOGL $QCOM

$KABN.ca North America Announces Closing of $1.15 Million Brokered Private Placement Financing $MOS.ca $MOGO.ca $CTZ.ca

Posted by AGORACOM-JC at 11:34 AM on Wednesday, December 23rd, 2020

Announced that it has closed its previously announced brokered private placement of units of the Company, pursuant to which the Company issued 7,666,667 Units at a price of $0.15 per Unit for aggregate gross proceeds of $1,150,000
The Offering was led by Mackie Research Capital Corporation as sole agent and sole bookrunner

TORONTO, ON / December 23, 2020 / KABN Systems NA Holdings Corp. (CSE:KABN) (the “Company” or “KABN North America” or “KABN NA“), a Canadian Fintech company that specializes in continuous online identity verification, management and monetization in Canada and the U.S., is pleased to announce that it has closed its previously announced brokered private placement of units of the Company (the “Units“), pursuant to which the Company issued 7,666,667 Units at a price of $0.15 per Unit (the “Offering Price“) for aggregate gross proceeds of $1,150,000 (the “Offering“). The Offering was led by Mackie Research Capital Corporation as sole agent and sole bookrunner (the “Agent“).

Each Unit is comprised of one common share of the Company (a “Common Share“) and one Common Share purchase warrant (a “Warrant“). Each Warrant is exercisable to acquire one Common Share (a “Warrant Share“) at an exercise price of $0.20 per Warrant Share, for a period of 24 months from the closing of the Offering.

The Company intends to use the net proceeds raised under the Offering for working capital and general corporate purposes.

In connection with the Offering, the Agent received an aggregate cash fee equal to 8.0% of the gross proceeds from the Offering including in respect of any exercise of the Agent’s Option. In addition, on closing the Company granted the Agent non-transferable compensation options (the “Compensation Options“) equal to 8.0% of the total number of Units sold under the Offering (including in respect of any exercise of the Agent’s Option). Each Compensation Option entitles the holder thereof to purchase one Unit at an exercise price equal to the Offering Price for a period of 24 months following the Closing.

In addition, the Company has paid the Agent a financial advisory fee satisfied by the issuance of 830,000 Common Shares.

The securities issued pursuant to the Offering are subject to a four-month and one day hold period under applicable securities laws in Canada.

The securities described herein have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act“), or any state securities laws, and accordingly, may not be offered or sold within the United States except in compliance with the registration requirements of the U.S. Securities Act and applicable state securities requirements or pursuant to exemptions therefrom. This press release does not constitute an offer to sell or a solicitation to buy any securities in any jurisdiction.

About KABN North America

KABN Systems NA Holdings Corp. through its wholly owned subsidiary KABN Systems North America Inc. focuses on the verification, management and monetization of digital identity, empowering users to control and benefit from the use of their online identity. KABN NA’s propriety technology suite includes 4 key products:

Liquid Avatar allows users to create high quality digital icons representing their online personas. These icons, in conjunction with KABN ID, allow users to manage and control their Self Sovereign Identity and to use Liquid Avatars to share verifiable credentials, including access, identity and designation credentials, and public and permission based private data when they want and with whom they want. www.liquidavatar.com

KABN ID is an Always On, biometric and blockchain based digital identity validation and verification platform allowing users to continuously and confidently prove themselves throughout the online community.

KABN Card is a Visa approved prepaid card program allowing users to manage both digital and fiat currencies and earn cashback and other loyalty incentives. www.kabncard.com

KABN KASH is a cashback, loyalty and engagement program that powers the KABN NA’s revenue ecosystem. KABN NA provides its products and services at no cost to consumers and generates revenues through permission-based partner programs. www.kabnkash.com

For more information, please visit www.kabnnaholdco.com or www.kabnsystemsna.com

KABN Systems NA Holding Corp. is a publicly listed company listed on the Canadian Securities Exchange under the symbol “KABN”.

For further information, please contact:

David Lucatch
647-725-7742 Ext. 701
[email protected]

The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

This news release does not constitute an offer to sell, or a solicitation of an offer to buy, any securities under the KABN Financing in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”) or any state securities laws and may not be offered or sold within the United States or to U.S. Persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.

Forward-Looking Information and Statements

This press release contains certain “forward-looking information” within the meaning of applicable Canadian securities legislation and may also contain statements that may constitute “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Such forward-looking information and forward-looking statements are not representative of historical facts or information or current condition, but instead represent only the Company’s beliefs regarding future events, plans or objectives, many of which, by their nature, are inherently uncertain and outside of the Company’s control. Generally, such forward-looking information or forward-looking statements can be identified by the use of forward-looking terminology such as “plans”, “expects” or “does not expect”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or may contain statements that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “will continue”, “will occur” or “will be achieved”. The forward-looking information and forward-looking statements contained herein may include, but is not limited to, information concerning the proposed use of the net proceeds of the Offering.

By identifying such information and statements in this manner, the Company is alerting the reader that such information and statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such information and statements. In addition, in connection with the forward-looking information and forward-looking statements contained in this press release, the Company has made certain assumptions. Among the key factors that could cause actual results to differ materially from those projected in the forward-looking information and statements are the following: changes in general economic, business and political conditions, including changes in the financial markets; changes in applicable laws; compliance with extensive government regulation. Should one or more of these risks, uncertainties or other factors materialize, or should assumptions underlying the forward-looking information or statements prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected.

Although the Company believes that the assumptions and factors used in preparing, and the expectations contained in, the forward-looking information and statements are reasonable, undue reliance should not be placed on such information and statements, and no assurance or guarantee can be given that such forward-looking information and statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information and statements. The forward-looking information and forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake to update any forward-looking information and/or forward-looking statements that are contained or referenced herein, except in accordance with applicable securities laws.

SOURCE: KABN Systems NA Holdings Corp.

Tags: blockchain, BOON, canadian fintech, Covid 19, crypto, CSE, kabn cash
Posted in KABN, KABN Systems NA Holdings Corp. | Comments Off on $KABN.ca North America Announces Closing of $1.15 Million Brokered Private Placement Financing $MOS.ca $MOGO.ca $CTZ.ca

CLIENT FEATURE: Universal #PropTech $UPI.ca Delivering Healthy Building Solutions and Services For Building Developers, Owners and Operators #AI #IoT $SNE $MSFT $HON

Posted by AGORACOM-JC at 9:43 AM on Wednesday, December 23rd, 2020

UPI: TSX-V

www.universalproptech.com

As the name implies “PropTech” is a combination of two words and stands for “property technology.” As simple as that is, the implementation and importance of PropTech is anything but.

Like every other industry on the planet that is incorporating technology to create greater efficiencies and experiences, the commercial real estate market is no different and is seeing the rapid adoption of;

Artificial Intelligence
Machine learning
Big data
Internet of Things (IoT Sensors)
Cloud computing

To create cost savings by reducing and even eliminating existing costs, create greater efficiencies for the operation and maintenance of real estate assets, as well as, improve the design of new builds.

IMPACT OF COVID-19

The COVID-19 pandemic has served to significantly increased the demand for PropTech in the commercial real estate market as follows:

The need for solutions to get workers back into workplace buildings and offices. Specifically, the need to identify bacteria and viruses in indoor air quality, as well as, the ability to sanitize immediately and effectively.
The need to create even greater cost savings and efficiencies for real estate owners that will continue suffering losses until workers significantly return to the workplace.

WHY UNIVERSAL PROPTECH (UPI:TSXV)?

Whereas many companies are just now trying to capitalize on the opportunities presented in the current and massive future of PropTech, Universal PropTech Inc. (“UPI”) a diversified investment platform delivering healthy building solutions and services for building developers, owners and operators in Canada. More than just lip service, UPI has been successfully delivering its PropTech solutions for years, with revenues over the last 3 years as follows:

2017 – $13.8M

2018 – $13.7M

2019 – $15.9M

Headquartered in Toronto, UPI has offices across Canada including Halifax,Montreal, and Ottawa.

COMPANY HIGHLIGHTS

Used in Federal Government facilities for over 40 years
Provides real estate managers turnkey HVAC Building Controls design, equipment, installation and ongoing operations and maintenance services for Industrial, Commercial, Institutional and Multi-residential customers
Already possesses under-utilized IP in building controls to add in additional monitoring inputs and equipment controls
Diverse revenue streams via products, installations and ongoing
Key strategic partnerships afford the ability to monitor real-time utility meters, key BAS and systems data in a building.
Team has the capability to make sense of this data and apply advanced web tools to make recommendations to fine tune a building, saving from 5% to 15% of a facilities energy spend without capital expenditure
VCI offers the depth and breadth of Building Automation Systems (BAS) knowledge and products from the likes of Siemens and Honeywell to support building automation systems

RECENT NEWS

COVID-19 STRATEGY

As businesses return to the office, property managers must think about the design and safety of their buildings for occupants. Traditional cleaning methods are ineffective at preventing transmission. UV technology is able to sanitize all surfaces free from pathogens. UPI is capitalizing on this opportunity by building and acquiring UV technology as it is the best in the market to administer and integrate it into healthy buildings in Canada.

FIND OUT MORE:

Hub On AGORACOM / Corporate Profile

Tags: AI, Big data, Cloud Computing, Delta-X Global Corp., investing, IOT, PropTech, small cap stocks, stocks, tsx
Posted in AGORACOM Client Feature, All Recent Posts, Universal PropTech Inc. | Comments Off on CLIENT FEATURE: Universal #PropTech $UPI.ca Delivering Healthy Building Solutions and Services For Building Developers, Owners and Operators #AI #IoT $SNE $MSFT $HON

Avicanna $AVCN.ca $AVCNF to Expand Access to Its Advanced and Evidence-Based RHO Phyto Medical Products Through Provincial Retailers Across Canada $WEED.ca $CL.ca $HEXO.ca

Posted by AGORACOM-JC at 7:52 AM on Wednesday, December 23rd, 2020

http://www.smallcapepicenter.com/Avicana%20square%20logo.jpg

Expanding from the successful launch in medical-only channels in partnership with Medical Cannabis by Shoppers, Avicanna will now offer RHO Phyto™ nationwide through provincial retailers
RHO Phyto products will include its advanced formulary of sublingual sprays, oil drops and topicals through retail sales channels estimated at $3 billion dollars* in Canada

TORONTO, Dec. 23, 2020 — Avicanna Inc. (“Avicanna” or the “Company“) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products, announces that the full formulary of RHO Phyto products will be available through retail channels in early 2021 in Canada.

A successful proof of concept and partnership with Medical Cannabis by Shoppers

During the past four months, the RHO Phyto medical formulary has experienced an incredibly successful launch with overwhelming positive support by the medical community including 300 prescribers and 20 clinics. RHO Phyto sales have increased 100%+ month over month in all product categories. The early results show the product formulary key demographics are 55% women, 47% are 51-75 years of age and 90% of consumers are 30+ years old. Avicanna will remain exclusive to Medical Cannabis by Shoppers for medical/prescription use and intends to increase its current commercial SKU’s from 4 to 10 in 2021.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/53b6cb70-2cb5-42b1-a891-f43366910e83

Expansion to retail sales to provide consumers with low barrier access to the same industry leading formulary of medical cannabis products

It has become evident that many consumers who seek cannabis for medical purposes are not going through medical channels, with nearly 44% purchasing from legal storefronts (adult-use). According to the 2020 Canadian Cannabis Survey, 76% of medical cannabis users do not have a medical document – such as a prescription – from a healthcare professional. The ease of access to store-fronts and systemic barriers to connecting with a health care professional who may provide a medical document have continued to impact medical user numbers year over year, which have remained largely the same around 350,000 active registered medical users in Canada since 2018*.

Aras Azadian, Avicanna’s Chief Executive Officer, stated: “The existing stigma around medical cannabis and the barriers to obtain a medical document make it particularly challenging for some patients to access medical cannabis through the appropriate channels with the support of a health care practitioner. We believe that by expanding the RHO Phyto portfolio into retail sales channels we will provide consumers with easier and low barrier access to standardized medical products they seek. For a biopharmaceutical company like Avicanna, this expansion of our medical products into retail channels is in many ways similar to accessing over-the-counter medical products.” Aras Azadian, the companies Chief Executive Officer.

RHO Phyto product attributes and retail sales strategy

The advanced and standardized products are offered in various doses of CBD, THC and THC-Free formulations to provide consumers with a range of inhalation-free cannabinoids-based solutions. The advanced formulations are developed and optimized by Avicanna to provide enhanced absorption versus basic MCT (medium-chain triglyceride) oil formulations while providing a consistent experience with a pleasant taste and smell. The RHO Phyto products are delivered with accurate dosing which also allows for easy titration and dosing by consumers.

Avicanna’s RHO Phyto strategy to leverage retail sales channels is consistent with the company’s vision to provide education and safe delivery of its products through evidenced-based training and education to the consumers, retailers and the medical community. Avicanna aims to establish RHO Phyto as the doctor recommended brand within the cannabis industry and has initiated several pre-clinical and real-world evidence clinical trials on the products with leading Canadian medical institutions.

*source: Statistics Canada

About Avicanna Inc.

Avicanna is a diversified and vertically integrated Canadian biopharmaceutical company focused on the research, development, and commercialization of plant-derived cannabinoid-based products for the global consumer, medical, and pharmaceutical market segments.

Avicanna is an established leader in cannabinoid research and development, which it primarily conducts at its R&D headquarters in the Johnson & Johnson Innovation Centre, JLABS @ Toronto, Canada and in collaboration with leading Canadian academic and medical institutions. In addition to its developing pharmaceutical pipeline, Avicanna’s team of experts have developed and commercialized several industry leading product lines, including:

Pura Earth™ or Pura H&W™: an advanced and clinically tested line of CBD consumer derma-cosmetic products; and,
RHO Phyto™: an advanced line of medical cannabis products containing varying ratios of CBD and THC currently available nation-wide across Canada in partnership with Medical Cannabis by Shoppers™, a subsidiary of Shoppers Drug Mart. RHO Phyto is the first strictly medical formulary of advanced “Cannabis 2.0” products, containing oils, sprays, capsules, creams, and gels, all 2 developed with scientific rigour, manufactured under GMP standards and supported by pre-clinical data.

With ongoing clinical trials on its derma-cosmetic (branded as Pura Earth or Pura H&W), medical cannabis (branded as RHO Phyto) and a pipeline of pharmaceutical products, Avicanna’s dedication to researching the important role that cannabinoids play in an increasingly wider scope of products has been at the core of the Company’s vision since its inception. Furthermore, Avicanna’s commitment to education is demonstrated through its annual medical symposium, the Avicanna Academy educational platform, and the My Cannabis Clinic patient program through its subsidiary company.

Avicanna manages its own supply chain including cultivation and extraction through its two majority-owned subsidiaries, Sativa Nativa S.A.S. and Santa Marta Golden Hemp S.A.S., both located in Santa Marta, Colombia. Through these sustainable, economical, and industrial scale subsidiaries, Avicanna cultivates, processes, and commercializes a range of cannabis and hemp cultivars dominant in CBD, CBG, THC, and other cannabinoids for use as active pharmaceutical ingredients. Avicanna’s Avesta Genetica program specializes in the development and optimization of rare cultivars for commercial production along with feminized seeds for global export. In June 2020, Avicanna made history with a shipment of hemp seeds to the United States of America by completing the first ever export of hemp seeds from Colombia.

SOURCE Avicanna Inc.

Stay Connected

For more information about Avicanna, visit www.avicanna.com, call 1-647-243-5283, or contact Setu Purohit, President by email at [email protected].

Cautionary Note Regarding Forward-Looking Information and Statements

This news release contains “forward-looking information” within the meaning of applicable securities laws. Forward-looking information contained in this press release may be identified by the use of words such as, “may”, “would”, “could”, “will”, “likely”, “expect”, “anticipate”, “believe, “intend”, “plan”, “forecast”, “project”, “estimate”, “outlook” and other similar expressions, and includes statements with respect to the ability of the Company to manufacture any of the products, and the ability of the Company to sell any of the products in retail channels in Canada. Forward-looking information is not a guarantee of future performance and is based upon a number of estimates and assumptions of management in light of management’s experience and perception of trends, current conditions and expected developments, as well as other factors relevant in the circumstances, including assumptions in respect of current and future market conditions, the current and future regulatory environment; and the availability of licenses, approvals and permits.

Although the Company believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because the Company can give no assurance that they will prove to be correct. Actual results and developments may differ materially from those contemplated by these statements. Forward-looking information is subject to a variety of risks and uncertainties that could cause actual events or results to differ materially from those projected in the forward-looking information. Such risks and uncertainties include, but are not limited to current and future market conditions, including the market price of the common shares of the Company, and the risk factors set out in the Company’s annual information form dated April 15, 2020 and final short form prospectus dated November 27, 2020, filed with the Canadian securities regulators and available under the Company’s profile on SEDAR at www.sedar.com .

The statements in this press release are made as of the date of this release. The Company disclaims any intent or obligation to update any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.

Tags: cannabinoids, Cannabis, Canopy Growth Corp, CBD, Cresco Labs Inc, CSE, Hexo Corp, Marijuana, Medical Cannabis by Shoppers, Rho Phyto, tsx
Posted in Avicanna Inc. | Comments Off on Avicanna $AVCN.ca $AVCNF to Expand Access to Its Advanced and Evidence-Based RHO Phyto Medical Products Through Provincial Retailers Across Canada $WEED.ca $CL.ca $HEXO.ca

Else Nutrition $BABY.ca $BABYF Expands Sprouts Farmers Market’s Formula Set with First Plant-based Non Dairy Toddler Nutrition Product in All Stores $BYND $VERY.ca $INGR $VEGN $TOFB

Posted by AGORACOM-JC at 7:14 AM on Wednesday, December 23rd, 2020

http://blog.agoracom.com/wp-content/uploads/2020/03/else-square-150x150.png

Announced today its plant-based toddler nutrition product will be available for purchase at Sprouts Farmers Market in February 2021
Consumers seeking healthy plant-based alternatives for their toddlers, will soon be able to find ELSE’s complete Toddler Nutrition product in over 360 Sprouts locations nationwide

VANCOUVER, BC , Dec. 23, 2020 /- ELSE NUTRITION HOLDINGS INC. (TSXV: BABY) (OTCQX: BABYF) (FSE: 0YL) (“Else” or the “Company”) , a provider of plant-based alternatives to dairy-based baby nutrition, announces today its plant-based toddler nutrition product will be available for purchase at Sprouts Farmers Market in February 2021 .

Consumers seeking healthy plant-based alternatives for their toddlers, will soon be able to find ELSE’s complete Toddler Nutrition product in over 360 Sprouts locations nationwide. The organic formula is primarily made of almonds, tapioca and buckwheat; three core ingredients that go through a clean, all-natural process that offers the protein, carbohydrates, and fat directly from the whole plants, along with phytonutrients, fiber, vitamins and minerals nature intended to provide optimal nourishment for children. Else is free of dairy, soy and corn-syrup, and is made with non-GMO ingredients.

“Being on the shelves at Sprouts Farmers Markets is an incredible milestone for our brand,” said Ms. Hamutal Yitzhak , CEO and Co-Founder of Else. “We are appreciative of the belief and support Sprouts has shown in our line of products, as they become the first natural grocery account to distribute Else on a national level. We have our sights set on being highly accessible across the United States , and this will begin with retailers who share our values and exceptionally high standards for progressive nutrition and ‘better-for-you’ foods.”

About Sprouts Farmers Market

True to its farm-stand heritage, Sprouts offers a unique grocery experience featuring an open layout with fresh produce at the heart of the store. Sprouts inspires wellness naturally with a carefully curated assortment of better-for-you products paired with purpose-driven people. The healthy grocer continues to bring the latest in wholesome, innovative products made with lifestyle-friendly ingredients such as organic, plant-based and gluten-free. Headquartered in Phoenix , and one of the fastest growing retailers in the country, Sprouts employs approximately 35,000 team members and operates more than 350 stores in 23 states nationwide.

About Else Nutrition Holdings Inc.

Else Nutrition GH Ltd. is an Israel -based food and nutrition company focused on developing innovative, clean and plant-based food and nutrition products for infants, toddlers, children, and adults. Its revolutionary, plant-based, non-soy, formula is a clean-ingredient alternative to dairy-based formula. Else Nutrition (formerly INDI) won the “2017 Best Health and Diet Solutions” award at the Global Food Innovation Summit in Milan . Else Toddler Nutrition was a #1 Best Seller on Amazon in the Baby/Toddler Formula Category in 2020. The holding company, Else Nutrition Holdings Inc., is a publicly traded company, listed as TSX Venture Exchange under the trading symbol BABY and is quoted on the US OTC Markets QX board under the trading symbol BABYF and on the Frankfurt Exchange under the symbol 0YL. Else’s Executives includes leaders hailing from leading infant nutrition companies. Many of Else advisory board members had past executive roles in companies such as Mead Johnson, Abbott Nutrition, Plum Organics and leading infant nutrition Societies, and some of them currently serve in different roles in leading medical centers and academic institutes such as Boston Children’s Hospital, Pediatrics at Harvard Medical School , USA , Tel Aviv University , Schneider Children’s Medical Center of Israel , Children’s Hospital of Colorado , Rambam Medical Center and Technion, Israel and University Hospital Brussels, Belgium .

For more information, visit: elsenutrition.com or @elsenutrition on Facebook and Instagram.

TSX Venture Exchange

Neither the TSX Venture Exchange nor its regulation services provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Caution Regarding Forward-Looking Statements

This press release contains statements that may constitute “forward-looking statements” within the meaning of applicable securities legislation. Forward-looking statements are typically identified by words such as “will” or similar expressions. Forward-looking statements in this press release include statements with respect to the anticipated dates for filing the Company’s financial disclosure documents. Such forward-looking statements reflect current estimates, beliefs and assumptions, which are based on management’s perception of current conditions and expected future developments, as well as other factors management believes are appropriate in the circumstances. No assurance can be given that the foregoing will prove to be correct. Forward-looking statements made in this press release assume, among others, the expectation that there will be no interruptions or supply chain failures as a result of COVID 19 and that the manufacturing, broker and supply logistic agreement with the Company do not terminate. Actual results may differ from the estimates, beliefs and assumptions expressed or implied in the forward-looking statements. Readers are cautioned not to place undue reliance on any forward-looking statements, which reflect management’s expectations only as of the date of this press release. The Company disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Tags: Amazon, baby food, Bristol-Myers Squibb Co, ConAgra Brands, CSE, gut health
Posted in Else Nutrition Holdings Inc. | Comments Off on Else Nutrition $BABY.ca $BABYF Expands Sprouts Farmers Market’s Formula Set with First Plant-based Non Dairy Toddler Nutrition Product in All Stores $BYND $VERY.ca $INGR $VEGN $TOFB

ImagineAR $IP.ca $IPNFF Provides Shareholders with 2020 Calendar Year Update, Including Record $775,000 in Executed Contracts $DBO.ca $YDX.ca $SEV.ca $NTAR.ca

Posted by AGORACOM-JC at 7:09 AM on Wednesday, December 23rd, 2020

http://www.smallcapepicenter.com/imagine%20ar%20squre.jpg

Though the Company has executed contracts totaling approximately $775,000 in the calendar year, the value of these contracts will not be fully reflected in the fiscal year financials due to the fact some of the agreements were signed after August 31.
Moreover, given the SaaS business model of the Company, revenues are recognized pro-rata over the life of the term of each contract, which can range from 1 – 5 years.
Nonetheless, the approximate $775,000 record revenue from these contracts will be received and recognized by the Company.

VANCOUVER, BC , Dec. 23, 2020 – Imagine AR Inc. (CSE: IP) (OTCQB: IPNFF) (“ImagineAR” or “Company”) an Augmented Reality Company that enables businesses, sports teams and organizations to create instant AR campaigns without a technical background, is pleased to provide investors with a corporate update for calendar 2020, the Company’s best year. Specifically, the Company set records in two key performance indicators (KPI’s):

Total Executed AR Contracts	$775,000 *
Total Proceeds from Financing	$6,000,000 (approximate)
* Approximate Augmented Reality Enterprise, White Label, and SDK contracts

ImagineAR CEO, Alen Paul Silverrstieen said “By every KPI, ImagineAR turned in its best calendar year performance ever. Despite the early negative impact to our sales pipeline as a result of COVID-19 shutting down live events, the pendulum swung quickly as sports teams, corporations and entertainers turned to augmented reality to generate new revenue opportunities through our platform’s ability to create direct mobile engagement and activations. We are very proud of our performance from both a sales and technology development point of view.”

The Company is filing its audited 2020 financials and MD&A for the fiscal year ended August 31, 2020 on SEDAR by the end of this month. Though the Company has executed contracts totaling approximately $775,000 in the calendar year, the value of these contracts will not be fully reflected in the fiscal year financials due to the fact some of the agreements were signed after August 31.

Moreover, given the SaaS business model of the Company, revenues are recognized pro-rata over the life of the term of each contract, which can range from 1 – 5 years. Nonetheless, the approximate $775,000 record revenue from these contracts will be received and recognized by the Company.

Silverrstieen added “Looking forward into 2021, though COVID-19 was a significant short-term catalyst in 2020, our pipeline clearly indicates it also accelerated the inevitable adoption of AR by 2-3 years, leading to our confident expectation that 2021 will see even greater increases than 2020. We fully expect to deliver news related to new contract wins in early 2021.”

Major New Global Clients

The Company had its best year of augmented reality contracts around the world in 2020.

Five Year White Label Contract with SlapitOnAR, a company owned and operated by true legends in the world of sports in the United States . CEO Mike Vanderjagt , NFL All-Pro Placekicker is the founder and his partners include Johnny Damon (MLB), Mike Modano (NHL), Troy Aikman (NFL), Steve Smith (NBA), and Cobi Jones (MLS).
Five Year White Label Contract with WaV Sports & Entertainment starting with a launch of the NFL Alumni Academy Subscription Mobile App early 2021.
Two Year Partnership with Valencia CF of La Liga in Spain installing the ImagineAR SDK in December 2020 .
Two Year Partnership with Royal Sociedad of La Liga in Spain installing the ImagineAR SDK in February 2021 .
Shoppers Drug Mart White Label Contract for Company-wide Training in 2021.
Business Partnership with India Music Superstar Ananya Birla to Launch ImagineAR for Consumers and Business in India . Ananya music videos have over 350 million views across all social platforms.

North American AR Consumer Campaigns

The Company launched three major consumer AR campaigns in North America .

Jacob “Stitch” Duran Promotion for the Fury vs. Wilder 2 Heavyweight Championship.
In partnership with the Broward Education Foundation, Flo Rida AR Campaign was launched in June 2020 . This AR campaign was covered in the United States by NBC, CBS, NPR, NY Times, Forbes, and many other media publications.
Free Virtual Santa Claus ImagineAR campaign was launched in December 2020 and has been already featured in media including CBS, The Guardian, KTLA, Military Families, and others.

$6,000,000 From Financing & Warrant Redemptions

Confidence in the Company’s augmented reality abilities was also demonstrated by the capital markets with ImagineAR receiving record proceeds from financing in 2020 of approximately $6,000,000 , including approximately $4,500,000 from the exercise of warrants over this summer. As a result, the Company is well financed for growth through to the end of 2021.

HOLIDAY WISHES

The Company wishes its investors in North America and across the world safe and happy holidays.

Most of all, ImagineAR extends its thanks and appreciation to all shareholders for their support and looks forward to achieving even greater things together in 2021.

This News Release is available on the company’s CEO Verified Discusion Forum , a moderated social media platform that enables civilized discussion and Q&A between Management and Shareholders.

About ImagineAR

ImagineAR Inc. (CSE: IP) (OTC: IPNFF) is an augmented reality (AR) platform, ImagineAR.com, that enables businesses of any size to create and implement their own AR campaigns with no programming or technology experience. Every organization, from professional sports franchises to small retailers, can develop interactive AR campaigns that blend the real and digital worlds. Customers simply point their mobile device at logos, signs, buildings, products, landmarks and more to instantly engage videos, information, advertisements, coupons, 3D holograms and any interactive content all hosted in the cloud and managed using a menu-driven portal. Integrated real-time analytics means that all customer interaction is tracked and measured in real-time. The AR Enterprise platform supports both IOS and Android mobile devices and upcoming wearable technologies.

All trademarks of the property of respective owners.

ON BEHALF OF THE BOARD

Alen Paul Silverrstieen
President & CEO
(818) 850-2490
https://twitter.com/IPtechAR
https://www.facebook.com/imaginationparktechnologies
https://www.instagram.com/iptechar
https://www.linkedin.com/company/imagination-park-technologies-inc

We encourage you to do your own due diligence and ask your broker if ImagineAR Inc. (cse: IP) is suitable for your particular investment portfolio*.

The Canadian Securities Exchange has neither approved nor disapproved the contents of this press release. This press release may include ‘forward-looking information’ within the meaning of Canadian securities legislation, concerning the business of the Company. The forward-looking information is based on certain key expectations and assumptions made by Imagination Park’s management. Although ImagineAR believes that the expectations and assumptions on which such forward- looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because ImagineAR can give no assurance that it will prove to be correct. These forward-looking statements are made as of the date of this press release, and ImagineAR disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.

Tags: Apple, AR, augmented reality, Camerai, CSE, D-BOX Technologies Inc., investment, small cap, small cap stocks, stocks, Tipit, tsx
Posted in All Recent Posts, Imagine AR | Comments Off on ImagineAR $IP.ca $IPNFF Provides Shareholders with 2020 Calendar Year Update, Including Record $775,000 in Executed Contracts $DBO.ca $YDX.ca $SEV.ca $NTAR.ca

VIDEO – Valeo Pharma $VPH.ca $VPHIF Blood Thinner Approval Projected To Thicken Revenues By $30 MILLION Per Year (Not A Typo) $HLS.ca $MDP.ca $GUD.ca $RX.ca

Posted by AGORACOM-JC at 6:00 PM on Tuesday, December 22nd, 2020

Valeo Pharma is already a successful, revenue generating, small cap Canadian pharmaceutical company that acquires the Canadian rights to commercialized drugs in other parts of the world that don’t have Canada on their radar as a target market.

This “in-license” business model is ingenious because it means ZERO developmental or clinical risk, which is the downfall of most small cap pharma companies.

This model has resulted in the following success:

$5.3M in revenues in the first 9 months of 2020 (ending July 31, 2020)
9 products currently in the market with an annual estimated peak sales of $40M/year
7 products in the pipeline with an annual estimated peak sales of $45M/year

In fact, capital markets confidence is so high that Valeo secured $8.6M in financing in the last half of the year with:

$6.9M Bought Deal financing at $1.20/shares
A $1.7M Oversubscribed debenture (non-convertible)

If that was all Valeo had, most investors would be happy to sit back and watch the Company grow.

But then came Redesca. We are going to save you the science and tell you that Redesca belongs to a class of anticoagulant medications (blood thinners) called LMWH. The size of the Canadian LMWH market is over $200M per year and Valeo believes they can capture 15-30% of this market. If you’re doing back of napkin math, that equates to $30,000,000 – $60,000,000 per year in revenues.

But how does a new product capture that much market share? Glad you asked because we asked CEO Steve Saviuk the same question. Competition is tough in all markets and they don’t let someone take 15-30% market share without one hell of a fight. Saviuk agreed and gave the following 3 reasons:

1. Redesca has an 8-year international track record of safety and efficacy. It is already well known

2. Redesca is flat out cheaper, which is music to the ears of Provincial Health Ministries whose budgets have been stretched to the max this year no thanks to COVID-19.

Vaelo is so confident that it stated “This is great news for the Canadian healthcare system …. and is expected to help provide significant savings to provincial healthcare systems.”

Well there you have it. Valeo is a great story. Watch the video.

HOLD ON. THERE’S MORE … A LOT MORE

In addition to being used primarily for treating and preventing deep vein thrombosis and pulmonary embolism, LMWH are also now increasingly used as a first line of defense tool in the fight against Covid-19. The World Health Organization’s (“WHO”) issued guidance regarding the prophylaxis use of LMWH to help prevent complications in the clinical management of severe acute respiratory infections when COVID-19 infection is suspected.

The Canadian market for LMWH was already at a healthy $200M + per year when Valeo started down the Redesca path 4 years ago. Now it gets the added kicker of Redesca being a first line of defense to fight COVID-19.

Now you have it. That’s the Valeo story as it applies to Redesca. There is a whole lot more to the story given their pipeline of products but we couldn’t cover it all in this great interview with CEO Steve Saviuk.

If you love revenue generating, growing and blue sky potential small cap companies, then this Valeo interview is a must watch.

Tags: BioSyent Inc., HLS Therapeutics, investment, Knight Therapeutics, Medexus Pharmaceuticals, pharma, pharma stocks, Redesca, small cap, small cap pharma, stocks, tsx
Posted in AGORACOM Via Satellite, All Recent Posts, Featured, Valeo Pharma Inc | Comments Off on VIDEO – Valeo Pharma $VPH.ca $VPHIF Blood Thinner Approval Projected To Thicken Revenues By $30 MILLION Per Year (Not A Typo) $HLS.ca $MDP.ca $GUD.ca $RX.ca

Author Archive

Categories